The deal provides Spero with a clinically validated pathway (CD40L) and a clear Phase 2 catalyst in Q2 2027, but the stock may re-rate on execution risk and financing needs. Monitor for any equity or debt offering to fund development, and watch for Innovent's Phase 2 SjD data in early 2027 as a read-through for the mechanism.
Price Chart
Executive Summary
Spero Therapeutics in-licensed global rights (ex-China) to SP001 (IBI355), a third-generation anti-CD40L antibody, from Innovent Biologics. The deal includes up to ~$1.1B in total milestones plus tiered royalties, and Spero plans a Phase 2 trial in IgG4-RD starting Q2 2027. This transaction transforms Spero's pipeline from infectious disease into immunology, but the asset is preclinical for Spero's lead indication and carries significant development risk.
Key Financial Metrics
Key Facts
- Spero receives exclusive global rights (ex-Greater China) to SP001 (IBI355), a third-generation Fc-silent anti-CD40L antibody.
- Total deal value up to ~$1.1B in development, regulatory, and commercial milestones plus tiered royalties on net sales.
- Spero plans to initiate a Phase 2 trial in IgG4-RD in Q2 2027; Innovent plans a Phase 2 in Sjögren's disease in China by early 2027.
- SP001 has completed Phase 1 SAD/MAD healthy volunteer studies and a Phase 1b MAD study in SjD (data presented at EULAR 2026).
- Spero is a clinical-stage biopharma with ~$126M market cap; this in-licensing establishes a new immunology pipeline.
Financial Impact
Up to ~$1.1 billion in milestone payments plus tiered royalties; no upfront payment amount disclosed.
Risk Factors
- SP001 is still preclinical for IgG4-RD; Phase 2 may fail or be delayed.
- Spero's small market cap (~$126M) may require dilutive financing to fund development.
- Competition from other anti-CD40L antibodies (e.g., amlitelimab, dapirolizumab) could limit commercial potential.
- Milestone payments to Innovent create a significant financial obligation if development succeeds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326657 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | EFFECT | $1.13 $1.13 | · 0.00% | ▼ −0.34% | $1.20 (−5.75%) |
Aug 28, 2026 4w ago | 8-K | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 28, 2026 4w ago | S-3 | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 12, 2026 7w ago | Press Release | $1.24 $1.22 | ▼ −1.61% | ▲ +0.35% | $1.20 (−3.63%) |
Jul 14, 2026 11w ago | 8-K | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jul 14, 2026 11w ago | Press Release | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jun 25, 2026 14w ago | 8-K | $2.26 $2.20 | ▼ −2.65% | ▼ −4.82% | $1.20 (−47.12%) |
Jun 22, 2026 14w ago | 8-K | $2.15 $2.26 | ▲ +5.12% | ▲ +4.10% | $1.20 (−44.42%) |
Jun 17, 2026 15w ago | Press Release | $2.11 $2.10 | ▼ −0.47% | ▲ +0.57% | $1.20 (−43.36%) |
May 13, 2026 20w ago | 8-K | $2.76 $2.69 | ▼ −2.54% | ▼ −1.82% | $1.20 (−56.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access